Medpace Holdings, Inc. Share Price

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 31/05/2024 BST 5-day change 1st Jan Change
386.3 USD +0.17% Intraday chart for Medpace Holdings, Inc. -1.08% +26.04%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.17B 170B Sales 2025 * 2.52B 198B Capitalization 11.94B 937B
Net income 2024 * 360M 28.24B Net income 2025 * 421M 33.02B EV / Sales 2024 * 5.17 x
Net cash position 2024 * 715M 56.06B Net cash position 2025 * 1.05B 82.44B EV / Sales 2025 * 4.32 x
P/E ratio 2024 *
34.4 x
P/E ratio 2025 *
29.5 x
Employees 5,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.17%
1 week-1.08%
1 month-1.21%
3 months-4.43%
6 months+40.28%
Current year+26.04%
More quotes
1 week
379.15
Extreme 379.15
397.55
1 month
379.15
Extreme 379.15
409.19
Current year
277.72
Extreme 277.72
421.00
1 year
207.47
Extreme 207.47
421.00
3 years
126.95
Extreme 126.945
421.00
5 years
53.10
Extreme 53.1
421.00
10 years
21.76
Extreme 21.76
421.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 30/06/92
Director of Finance/CFO 49 31/10/18
President 49 30/09/07
Members of the board TitleAgeSince
Director/Board Member 72 12/08/18
Chief Executive Officer 67 30/06/92
Director/Board Member 64 12/08/18
More insiders
Date Price Change Volume
31/05/24 386.3 +0.17% 292,758
30/05/24 385.7 -0.59% 146,146
29/05/24 388 -0.72% 240,223
28/05/24 390.8 +0.07% 170,029

Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm

More quotes
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
386.3 USD
Average target price
428.2 USD
Spread / Average Target
+10.85%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW